

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2015

DESPATCHED ON 20TH JANUARY 2015

HLA PHENOTYPE OF BLOOD DONOR: HLA-A32, A68; B27, B44; Cw2, Cw5; DR11, DR13, DQ6, DQ7

Summary of Results								
PBL/T-Cells					B-Cells			
Total tested	20	20	20	20	17	17	17	17
Positive	20	19	0	2	17	16	6	9
Negative	0	1	20	18	0	1	11	8
NT/Equivocal	1	1	1	1	3	3	3	3
% Positive	100.0%	95.0%	0.0%	10.0%	100.0%	94.1%	35.3%	52.9%
% Negative	0.0%	5.0%	100.0%	90.0%	0.0%	5.9%	64.7%	47.1%
Consensus	Positive	Positive	Negative	Negative	Positive	Positive	Not Assessed	Not Assessed
HLA Antibody (Defined By CDC)	A3, B7, B27, B22	B14+	DR17	B51	A3, B7, B27, B22	B14+	DR17	B51
Lab No.	Without DTT				Without DTT			
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4
9	Positive	Positive	Negative	Negative	Positive	Positive	Positive	Negative
11	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
12	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Positive
14	Positive	Positive	Negative	Negative	Positive	Positive	Positive	Positive
15	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative
20	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
23	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
24	Positive	Positive	Negative	Negative	Positive	Positive	Positive	Positive
25	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
28	Positive	Weak Positive	Negative	Negative	NT	NT	NT	NT
34	Positive	Positive	Negative	Negative	NT	NT	NT	NT
35	Positive	Positive	Negative	Negative				
38	Positive	Positive	Negative	Negative	Positive	Negative	Negative	Negative
39	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Positive
41	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
42	Positive	Positive	Negative	Negative	Positive	Positive	Weak Positive	Weak Positive
45	Positive	Positive	Negative	Positive	Positive	Positive	Positive	Positive
51	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Positive
54	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Positive
58	NT	NT	NT	NT	NT	NT	NT	NT
62	Positive	Positive	Negative	Negative	Positive	Positive	Positive	Positive

B-cells not tested due to poor cell viability
B-cells not tested due to poor cell viability

Concern with reliability of results due to viability

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2015

DESPATCHED ON 20TH JANUARY 2015

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	6	6	0	0	6	4	2	0		90	90
11	8	6			8	6				90	90
12	100%	95%	3%	5%	100%	100%	5%	40%		98	95
14	8	8	0	0	8	8	8	8		90	60
15	8				8	2			90	90	85
20	9	9	1	1	9	9	1	1	50	90	90
23	8	6	1	1	8	8	1	1		90	90
24	100	100	10	20	90	90	50	40		90	80
25	8	6	1	1	8	8	1	1		99	99
28	8	4	1	1	NT	NT	NT	NT		99	0
34	8	8	1	1	NT	NT	NT	NT		99	40
35	6	6	1	1					60	70	
38	8	8	1	1	8	1	1	1	90	95	95
39	4	4			6	6		4	97		97
41	60%	40%			90%	40%				95	90
42	80%-100%	60-80%			80-100%	40-60%	20-40%	20%	95		85
45	8	8	1	2/4	8	8	4	6		99	80
51	6-8	6-8	0	2-4	6-8	4-6	0	4-6		95	95
54	90-100%	60-70%	5-15%	5-15%	90-100%	70-80%	0	50-60%		95	80
58	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
62	8	8	0	0	8	8	8	6		100	90

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2015

DESPATCHED ON 20TH JANUARY 2015

HLA PHENOTYPE OF BLOOD DONOR: HLA-A32, A68; B27, B44; Cw2, Cw5; DR11, DR13, DQ6, DQ7

Summary of Results								
PBL/T-Cells					B-Cells			
Total tested	17	17	17	17	14	13	14	14
Positive	15	15	0	0	13	12	4	0
Negative	2	2	17	17	1	1	10	14
NT/Equivocal	1	1	1	1	3	4	3	3
% Positive	88.2%	88.2%	0.0%	0.0%	92.9%	92.3%	28.6%	0.0%
% Negative	11.8%	11.8%	100.0%	100.0%	7.1%	7.7%	71.4%	100.0%
Consensus	Positive	Positive	Negative	Negative	Positive	Positive	Not Assessed	Negative
HLA Antibody (Defined By CDC)	A3, B7, B27, B22	B14+	DR17	B51	A3, B7, B27, B22	B14+	DR17	B51
Lab No.	Serum 1	With DTT			Serum 1	With DTT		
		Serum 2	Serum 3	Serum 4		Serum 2	Serum 3	Serum 4
9	Positive	Positive	Negative	Negative	Positive	Positive	Positive	Negative
11	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
12	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
14	Positive	Positive	Negative	Negative	Positive	Positive	Positive	Negative
15	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
20	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
24	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
25	Positive	Positive	Negative	Negative	Positive	NT	Negative	Negative
28	Negative	Negative	Negative	Negative	NT	NT	NT	NT
34	Positive	Positive	Negative	Negative	NT	NT	NT	NT
35	Positive	Positive	Negative	Negative				
38	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
39	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
41	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
42	Positive	Positive	Negative	Negative	Positive	Positive	Positive	Negative
45	Positive	Positive	Negative	Negative	Positive	Positive	Positive	Negative
51	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative
58	NT	NT	NT	NT	NT	NT	NT	NT

system failure serum 2 B cell
B-cells not tested due to poor cell viability
B-cells not tested due to poor cell viability

Concern with reliability of results due to viability

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2015

DESPATCHED ON 20TH JANUARY 2015

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	6	6	0	0	6	4	2	0		90	90
11	8	8			6	6				90	90
12	100%	100%	5%	5%	100%	100%	5%	5%		98	95
14	6	6	0	0	8	8	8	0		90	60
15	8	4			8	6			90	90	85
20	9	9	1	1	9	9	1	1	50	90	90
24	90	100	10	10	80	80	30	20		90	80
25	8	6	1	1	8	NT	1	1		99	99
28	1	1	1	1	NT	NT	NT	NT		99	0
34	8	8	1	1						99	40
35	4	4	1	1					60	70	
38	8	6	1	1	8	4	1	1	90	95	95
39									97		97
41	70%	70%			35%	25%				95	90
42	40-60%	40-60%			80-100%	60-80%	40-60%		95		85
45	8	8	1	1	8	8	4	1		99	80
51	6-8	4-6	0	0	6	4-6	0	0		95	95
58	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT